Literature DB >> 24084704

Molecular imaging of prostate cancer with PET.

Hossein Jadvar.   

Abstract

Molecular imaging is paving the way for precision and personalized medicine. In view of the significant biologic and clinical heterogeneity of prostate cancer, molecular imaging is expected to play an important role in the evaluation of this prevalent disease. The natural history of prostate cancer spans from an indolent localized process to biochemical relapse after radical treatment with curative intent to a lethal castrate-resistant metastatic disease. The ongoing unraveling of the complex tumor biology of prostate cancer uniquely positions molecular imaging with PET to contribute significantly to every clinical phase of prostate cancer evaluation. The purpose of this article was to provide a concise review of the current state of affairs and potential future developments in the diagnostic utility of PET in prostate cancer.

Entities:  

Keywords:  PET; PET/CT; PET/MRI; cancer; correlative imaging; imaging; molecular; molecular imaging; oncology; prostate; radiopharmaceuticals

Mesh:

Substances:

Year:  2013        PMID: 24084704     DOI: 10.2967/jnumed.113.126094

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  30 in total

1.  The Utility of [18F]DASA-23 for Molecular Imaging of Prostate Cancer with Positron Emission Tomography.

Authors:  Corinne Beinat; Tom Haywood; Yun-Sheng Chen; Chirag B Patel; Israt S Alam; Surya Murty; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

2.  Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.

Authors:  Catharina M van Rij; Cathelijne Frielink; David M Goldenberg; Robert M Sharkey; Gerben M Franssen; Susanne Lütje; William J McBride; Wim J G Oyen; Otto C Boerman
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

3.  ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.

Authors:  Steven P Rowe; Kenneth L Gage; Sheila F Faraj; Katarzyna J Macura; Toby C Cornish; Nilda Gonzalez-Roibon; Gunes Guner; Enrico Munari; Alan W Partin; Christian P Pavlovich; Misop Han; H Ballentine Carter; Trinity J Bivalacqua; Amanda Blackford; Daniel Holt; Robert F Dannals; George J Netto; Martin A Lodge; Ronnie C Mease; Martin G Pomper; Steve Y Cho
Journal:  J Nucl Med       Date:  2015-06-11       Impact factor: 10.057

4.  Vertebral and femoral bone mineral density and bone strength in prostate cancer patients assessed in phantomless PET/CT examinations.

Authors:  Benedikt J Schwaiger; David L Kopperdahl; Lorenzo Nardo; Luca Facchetti; Alexandra S Gersing; Jan Neumann; Kwang J Lee; Tony M Keaveny; Thomas M Link
Journal:  Bone       Date:  2017-04-24       Impact factor: 4.398

Review 5.  The Warburg effect: evolving interpretations of an established concept.

Authors:  Xiaozhuo Chen; Yanrong Qian; Shiyong Wu
Journal:  Free Radic Biol Med       Date:  2014-09-30       Impact factor: 7.376

Review 6.  Prognostic Utility of PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2015-01-22

7.  The changing role of imaging in clinical care.

Authors:  Rahul Aggarwal; John Kurhanewicz
Journal:  Nat Rev Urol       Date:  2014-01-14       Impact factor: 14.432

8.  Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.

Authors:  Yong-Il Kim; Gi Jeong Cheon; Jin Chul Paeng; Jeong Yeon Cho; Cheol Kwak; Keon Wook Kang; June-Key Chung; Euishin Edmund Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-11       Impact factor: 9.236

Review 9.  Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET.

Authors:  Phillip J Koo; Jennifer J Kwak; Sajal Pokharel; Peter L Choyke
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

Review 10.  Current Status of Hybrid PET/MRI in Oncologic Imaging.

Authors:  Andrew B Rosenkrantz; Kent Friedman; Hersh Chandarana; Amy Melsaether; Linda Moy; Yu-Shin Ding; Komal Jhaveri; Luis Beltran; Rajan Jain
Journal:  AJR Am J Roentgenol       Date:  2015-10-22       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.